testis specific protein Y-linked 26, pseudogeneGenealiases: TSPYL3 · bA392M18.1
Q-omics provides the consensus-scored TSPY26P profile across patient tissues and cancer cell-line models. TSPY26P expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TSPY26P is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TSPY26P RNA expression shows 18,960 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where TSPY26P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPY26P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPY26P survival associations across molecular data types. TSPY26P RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPY26P RNA expression–survival associations across cancer types. High TSPY26P expression shows unfavorable associations in STAD, but favorable associations in HNSC, UVM, BRCA, LGG and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TSPY26P RNA expression.
This table summarizes TSPY26P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TSPY26P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPY26P shows lower tumor expression in KIRC, KIRP, UCEC and KICH and higher tumor expression in HNSC and LUSC. The KIRC box plot shows higher TSPY26P RNA expression in normal versus tumor tissue (log2 FC = −1.366, t-test p < 0.001).
This table shows molecular features associated with TSPY26P in patient tissues and cancer cell lines. In patient samples, TSPY26P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
